EMA Calls for Stepwise Approach to Biosimilar Monoclonal Antibodies
Developers of biosimilar monoclonal antibodies (mAb) must conduct nonclinical and clinical studies that compare the biosimilars with the original mAb to detect any relevant differences between the two products, according to a final European Medicines Agency (EMA) guideline.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.